	US 12,291,538 B2
	Small molecule inhibitors of KRAS G12C mutant
Indu Bharathan, Somerville, MA (US); Symon Gathiaka, Waltham, MA (US); Yongxin Han, Needham, MA (US); Xiaoshen Ma, Boston, MA (US); Ryan D. Otte, Natick, MA (US); David L. Sloman, Newton, MA (US); Thomas H. Graham, Somerville, MA (US); Timothy Henderson, Natick, MA (US); Elisabeth Hennessy, Weston, MA (US); and Anandan Palani, Needham, MA (US)
Assigned to Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed by Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed on May 3, 2023, as Appl. No. 18/311,646.
Application 18/311,646 is a division of application No. 17/081,477, filed on Oct. 27, 2020, granted, now 11,697,657.
Claims priority of provisional application 63/030,014, filed on May 26, 2020.
Claims priority of provisional application 62/926,879, filed on Oct. 28, 2019.
Prior Publication US 2024/0043448 A1, Feb. 8, 2024
Int. Cl. C07D 498/22 (2006.01); A61K 31/519 (2006.01); A61P 35/00 (2006.01); C07D 471/22 (2006.01); C07D 519/00 (2006.01)

CPC C07D 498/22 (2013.01) [A61K 31/519 (2013.01); A61P 35/00 (2018.01); C07D 471/22 (2013.01); C07D 519/00 (2013.01); C07B 2200/05 (2013.01)]

6 Claims

1. A method of inhibiting KRAS G12C protein comprising contacting KRAS G12C protein with a compound or a pharmaceutically acceptable salt thereof, to inhibit the activity of the KRAS G12C protein, wherein the compound is selected from the group consisting of: